Organon Pays Three Generic Firms $28 Mil. To Settle Remeron Antitrust Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan's share of the settlement is $15 mil. Akzo Nobel subsidiary Organon is concluding a separate, tentative settlement with third-party payors and consumers of the antidepressant.